Evelo Biosciences Inc (EVLO)

Evelo Biosciences Stock Analysis & Ratings

EVLO Stock Chart & Stats

Day’s Range$1.77 - $1.81
52-Week Range$1.59 - $17.13
Previous Close$1.77
Average Volume (3M)316.96K
Market Cap$94.98M
P/E Ratio-0.8
Next EarningsAug 04, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score2
EPS (TTM)-2.31



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Evelo Biosciences’s price range in the past 12 months?
Evelo Biosciences lowest stock price was $1.59 and its highest was $17.13 in the past 12 months.
    What is Evelo Biosciences’s market cap?
    Evelo Biosciences’s market cap is $94.98M.
      What is Evelo Biosciences’s price target?
      The average price target for Evelo Biosciences is $12.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $20.00 ,the lowest forecast is $6.00. The average price target represents 615.82% Increase from the current price of $1.77.
        What do analysts say about Evelo Biosciences?
        Evelo Biosciences’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Evelo Biosciences’s upcoming earnings report date?
          Evelo Biosciences’s upcoming earnings report date is Aug 04, 2022 which is in 78 days.
            How were Evelo Biosciences’s earnings last quarter?
            Evelo Biosciences released its earnings results on May 12, 2022. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.564 by $0.004.
              Is Evelo Biosciences overvalued?
              According to Wall Street analysts Evelo Biosciences’s price is currently Undervalued.
                Does Evelo Biosciences pay dividends?
                Evelo Biosciences does not currently pay dividends.
                What is Evelo Biosciences’s EPS estimate?
                Evelo Biosciences’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Evelo Biosciences have?
                Evelo Biosciences has 53,660,000 shares outstanding.
                  What happened to Evelo Biosciences’s price movement after its last earnings report?
                  Evelo Biosciences reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.564. Following the earnings report the stock price went down -9.662%.
                    Which hedge fund is a major shareholder of Evelo Biosciences?
                    Among the largest hedge funds holding Evelo Biosciences’s share is Flagship Pioneering Inc.. It holds Evelo Biosciences’s shares valued at 78M.


                      Evelo Biosciences Stock Analysis

                      Smart Score
                      Price Target
                      ▲(615.82% Upside)
                      Strong Buy
                      The Evelo Biosciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Evelo Biosciences Inc

                      Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

                      Similar Stocks
                      Price & Change
                      Rubius Therapeutics
                      Scholar Rock Holding
                      Kiniksa Pharmaceuticals
                      Magenta Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis